Archemix Announces Completion of Phase 1 Trial of ARC1779
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 8, 2007 - Archemix Corp., a
biotechnology company focused on discovering and developing
aptamers, announced the successful completion of a Phase 1 study of
its novel aptamer therapeutic, ARC1779. ARC1779
is designed to
selectively block the activation, adhesio...
Archemix : Products : ARC1779 in TMA
We believe that ARC1779
can bind to and inhibit the activity of ... In March 2007, we completed a Phase 1 clinical trial of ARC1779
in 47 healthy volunteers. ...
Archemix : Products : Product Pipeline
Our aptamer product candidate, ARC1779
, is a PEGylated aptamer consisting of 40 ... We believe that ARC1779
, with its potential to inhibit the function of vWF, ...
Archemix' ARC1779 Granted Orphan Designation in EU for the Treatment of ...ARC1779
, a novel aptamer therapeutic, is a first-in-class anti-platelet agent ... ARC1779
is designed to bind to and inhibit a protein known as von Willebrand ...
Effect of ARC1779 on Cerebral Microembolism in Patients Undergoing ...
To determine the effect of ARC1779
on the incidence of new ischemic lesions ... To assess the relationships among ARC1779
PD, PK, and the frequency of cerebral ...
Portfolio Company NewsARC1779
is an novel aptamer therapeutic designed to bind to and inhibit vWF, ... This Phase 2 trial of ARC1779
in TTP is being conducted at the Medical ...
Archemix Initiates Phase 2a for Lead Aptamer Product Candidate ARC1779
Company Achieves Key Clinical Milestone with Initiation of Second Phase 2 Trial for ARC1779
... the pharmacokinetic and pharmacodynamic profile of ARC1779